Atlanta Journal Constitution - TUESDAY, Jan. 15 (HealthDay News) -- Tysabri (natalizumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe Crohn's disease in people who haven't responded to other therapies. Tysabri, made by the Ireland-based ...